Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project
Dale W Bratzler1, Allen Ma, Wato Nsa
1Oklahoma Foundation for Medical Quality, Oklahoma City, OK 73134, USA. dbratzler@okqio.sdps.org
Background:
Guidelines for empirical treatment of hospitalized patients with pneumonia provide specific recommendations for antibiotic selection that are primarily based on findings from observational studies.
Methods:
We conducted a retrospective study of 27,330 community-dwelling, immunocompetent Medicare patients (age, >65 years) with pneumonia who were hospitalized in 1998-1999 and 2000-2001. Associations between initial antimicrobial regimens and risk-adjusted mortality were assessed, accounting for differences in patient characteristics, comorbidities, illness severity, geographic location, and processes of care. Treatment with nonpseudomonal third-generation cephalosporin monotherapy constituted the reference group for comparisons.
Results:
For patients not in the intensive care unit, initial treatment with fluoroquinolone monotherapy was associated with reduced in-hospital mortality, 14-day mortality, and 30-day mortality rates (adjusted odds ratio [AOR] for 30-day mortality, 0.7; 95% confidence interval [CI], 0.6-0.9; P = .001). The combination of a cephalosporin plus a macrolide was associated with reduced 14-day and 30-day mortality rates (AOR for 30-day mortality, 0.7; 95% CI, 0.6-0.9; P < .001). For intensive care unit patients, the combination of a cephalosporin and a macrolide was associated with reduced in-hospital mortality (AOR, 0.6; 95% CI, 0.3-0.9; P = .018).
Conclusions:
Initial antimicrobial treatment with the combination of a second- or third-generation cephalosporin and a macrolide or initial treatment with a fluoroquinolone was associated with a reduced 30-day mortality rate, compared with treatment with third-generation cephalosporin monotherapy, among non-intensive care unit patients. Although our results are consistent with other observational studies, controversy continues to exist about the use of nonexperimental cohort studies to demonstrate associations between processes of care, such as antibiotic selection, and patient outcomes.
Insights
Effective pneumonia treatment for older adults involves specific antibiotic choices. Fluoroquinolone monotherapy or cephalosporin-macrolide combinations reduce 30-day mortality compared to cephalosporin monotherapy in non-ICU patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Geriatrics
Background:
- Current pneumonia treatment guidelines rely on observational studies for antibiotic selection.
- Empirical antibiotic therapy is crucial for hospitalized pneumonia patients.
Purpose of the Study:
- To assess the association between initial antimicrobial regimens and mortality in elderly, immunocompetent Medicare patients with pneumonia.
- To compare the effectiveness of different antibiotic strategies.
Main Methods:
- Retrospective study of 27,330 Medicare patients aged over 65 with pneumonia.
- Analysis of risk-adjusted mortality based on initial antibiotic regimens, controlling for patient characteristics, comorbidities, and illness severity.
- Nonpseudomonal third-generation cephalosporin monotherapy used as the reference treatment group.
Main Results:
- For non-intensive care unit (ICU) patients, fluoroquinolone monotherapy reduced in-hospital, 14-day, and 30-day mortality (AOR 0.7 for 30-day mortality).
- Cephalosporin-macrolide combination therapy also reduced 14-day and 30-day mortality in non-ICU patients (AOR 0.7 for 30-day mortality).
- In ICU patients, cephalosporin-macrolide combination therapy was linked to reduced in-hospital mortality (AOR 0.6).
Conclusions:
- Initial treatment with fluoroquinolone or cephalosporin-macrolide combination therapy is associated with lower 30-day mortality in non-ICU pneumonia patients compared to cephalosporin monotherapy.
- Findings align with other observational studies but highlight ongoing debate regarding nonexperimental study designs for process-outcome associations.
- Antibiotic selection is a critical process of care impacting patient outcomes in pneumonia.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:14Atypical Pneumonia
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: